BillionToOne Partners with National Cancer Center Hospital East for Liquid Biopsy Study in Japan

Reuters01-06

BillionToOne Partners with National Cancer Center Hospital East for Liquid Biopsy Study in Japan

BillionToOne Inc. has announced a collaboration with the National Cancer Center Hospital East (NCCHE) in Japan, as its ultra-sensitive liquid biopsy test, Northstar Select®, has been selected for use in the LC-SCRUM-TRY clinical study. This partnership aims to expand precision medicine access for patients with treatment-resistant non-small cell lung cancer (NSCLC) in Japan. By integrating Northstar Select into the nationwide, multi-center study, the collaboration seeks to better characterize drug-resistant cancers and identify more effective therapies for affected patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Billiontoone Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA56378) on January 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2601881864?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-06 22:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601881864","market":"fut","top_or_hot":-1,"title":"BillionToOne Partners with National Cancer Center Hospital East for Liquid Biopsy Study in Japan","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BillionToOne Partners with National Cancer Center Hospital East for Liquid Biopsy Study in Japan\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BillionToOne Inc. has announced a collaboration with the National Cancer Center Hospital East (NCCHE) in Japan, as its ultra-sensitive liquid biopsy test, Northstar Select®, has been selected for use in the LC-SCRUM-TRY clinical study. This partnership aims to expand precision medicine access for patients with treatment-resistant non-small cell lung cancer (NSCLC) in Japan. By integrating Northstar Select into the nationwide, multi-center study, the collaboration seeks to better characterize drug-resistant cancers and identify more effective therapies for affected patients.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Billiontoone Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA56378) on January 06, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BillionToOne Partners with National Cancer Center Hospital East for Liquid Biopsy Study in Japan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBillionToOne Partners with National Cancer Center Hospital East for Liquid Biopsy Study in Japan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-06 22:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BillionToOne Partners with National Cancer Center Hospital East for Liquid Biopsy Study in Japan\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BillionToOne Inc. has announced a collaboration with the National Cancer Center Hospital East (NCCHE) in Japan, as its ultra-sensitive liquid biopsy test, Northstar Select®, has been selected for use in the LC-SCRUM-TRY clinical study. This partnership aims to expand precision medicine access for patients with treatment-resistant non-small cell lung cancer (NSCLC) in Japan. By integrating Northstar Select into the nationwide, multi-center study, the collaboration seeks to better characterize drug-resistant cancers and identify more effective therapies for affected patients.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Billiontoone Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA56378) on January 06, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BLLN","symbol_name":"BillionToOne, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDL37XJQv:1","article_id":"2601881864","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601881864","pubTimestamp":1767708084,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BillionToOne Inc. has announced a collaboration with the National Cancer Center Hospital East  in Japan, as its ultra-sensitive liquid biopsy test, Northstar Select, has been selected for use in the LC-SCRUM-TRY clinical study. This partnership aims to expand precision medicine access for patients with treatment-resistant non-small cell lung cancer  in Japan. By integrating Northstar Select into the nationwide, multi-center study, the collaboration seeks to better characterize drug-resistant cancers and identify more effective therapies for affected patients.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Billiontoone Inc. published the original content used to generate this news brief via PR Newswire  on January 06, 2026, and is solel","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BLLN":"BillionToOne, Inc.","BK4205":"房地产经营公司","BK4233":"房地产运营公司","BK4135":"资产管理与托管银行","BK4160":"多样化房地产投资信托v","BK4196":"保健护理服务","DBRG":"DigitalBridge Group, Inc."},"translate_title":"BillionToOne与东国立癌症中心医院合作在日本进行液体活检研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DBRG":0.9,"BLLN":0.9},"content_text":"BillionToOne Partners with National Cancer Center Hospital East for Liquid Biopsy Study in Japan\n    \n\n        BillionToOne Inc. has announced a collaboration with the National Cancer Center Hospital East (NCCHE) in Japan, as its ultra-sensitive liquid biopsy test, Northstar Select®, has been selected for use in the LC-SCRUM-TRY clinical study. This partnership aims to expand precision medicine access for patients with treatment-resistant non-small cell lung cancer (NSCLC) in Japan. By integrating Northstar Select into the nationwide, multi-center study, the collaboration seeks to better characterize drug-resistant cancers and identify more effective therapies for affected patients.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Billiontoone Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA56378) on January 06, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601881864","isCrawlerRequest":true}